Mural Oncology plc
MURA$32M
Micro CapNASDAQPharmaceutical Preparations🇺🇸North AmericaDUBLIN 2116 employees
Drugs in Pipeline
4
Phase 3 Programs
0
Upcoming Catalysts
0
Next Catalyst
None scheduled
Market Overview
Stock performance and key metrics
MURA News
Catalyst Timeline
0 upcoming, 0 past
No catalysts found.
Drug Pipeline
Pembrolizumab
Squamous Cell Carcinoma of Head and Neck
Nemvaleukin alfa
Advanced Solid Tumor
ALKS 4230 + pembrolizumab
Advanced Solid Tumors
ALKS 4230
Advanced Solid Tumors
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Pembrolizumab | Phase 2 | Squamous Cell Carcinoma of Head and Neck | - | - |
Nemvaleukin alfa | Phase 2 | Advanced Solid Tumor | - | - |
ALKS 4230 + pembrolizumab | Phase 2 | Advanced Solid Tumors | - | - |
ALKS 4230 | Phase 2 | Advanced Solid Tumors | - | - |
Regulatory Approvals
Data is aggregated from public sources (FDA, SEC, ClinicalTrials.gov). While we strive for accuracy, information may be incomplete, delayed, or contain errors. Terms apply